Idenix Restructures, Amends Collaboration with Novartis
Idenix Pharmaceuticals, Inc. (Cambridge, MA), has announced a strategic restructuring and an amended collaboration agreement with Novartis Pharma AG related to Sebivo (also marketed as Tyzeka), an oral treatment for patients with chronic hepatitis B.
Idenix Pharmaceuticals, Inc. (Cambridge, MA), has announced a strategic restructuring and an amended collaboration agreement with Novartis Pharma AG related to Sebivo (also marketed as Tyzeka), an oral treatment for patients with chronic hepatitis B.
According to the amended agreement, Idenix will discontinue all development, manufacturing, and commercial activities for Sebivo. Novartis will have full responsibility for ongoing and future clinical trials and regulatory filings related to Sebivo. Idenix will receive a royalty on worldwide product sales. As a result of the changes, Idenix is reducing its workforce of 300 persons by approximately 100 positions, the majority of which support the development and commercialization of Sebivo in the US and Europe.
The changes will allow Idenix to focus on its HCV and HIV programs. Idenix currently has a non-nucleoside reverse transcriptase inhibitor, IDX899, for the treatment of HIV-1, which is being evaluated in Phase 1 and 2 clinical testing. The company also has a comprehensive HCV discovery effort, comprising a next-generation nucleoside polymerase inhibitor program, including IDX102 and IDX184, which are being evaluated in preclinical testing, and HCV non-nucleoside polymerase inhibitor and HCV protease inhibitor programs.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
